Growth factor receptor kinase inhibitors: recent progress and clinical impact.
Inhibition of growth factor receptor kinases is one of the most promising therapeutic approaches for the treatment of cancer. This review focuses on the most recent progress in this area, and gives an overview of the compounds currently in the clinic, as well as key preclinical analogs.
Dumas
J
J
Bayer Research Center, Bayer Corporation, Pharmaceutical Division, 400 Morgan Lane, West Haven, CT 06516, USA. jacques.dumas.b@bayer.com
D000818:Animals; D004791:Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000502:physiology; D017978:Receptors, Growth Factor / Q000037:antagonists & inhibitors* / Q000502:physiology
D004791:Enzyme Inhibitors; D017978:Receptors, Growth Factor; D020794:Receptor Protein-Tyrosine Kinases